Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoadjuvant Operable Breast Cancer × Cyclophosphamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 322 Precursor Cell Lymphoblastic Leukemia-Lymphoma 290 Lymphoma 272 Leukemia 235 Multiple Myeloma 223 Lymphoma, Large B-Cell, Diffuse 218 Lymphoma, Non-Hodgkin 215 Leukemia, Myeloid, Acute 210 Leukemia, Lymphocytic, Chronic, B-Cell 199 Myelodysplastic Syndromes 167 Lymphoma, Follicular 161 Hodgkin Disease 154 Lymphoma, Mantle-Cell 148 Burkitt Lymphoma 146 Lymphoma, B-Cell, Marginal Zone 107 Recurrence 105 Lymphoma, Large-Cell, Immunoblastic 88 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 73 Myeloproliferative Disorders 72 Melanoma 72 Neoplasms, Plasma Cell 70 Leukemia, Myeloid, Accelerated Phase 67 Leukemia, Myelomonocytic, Chronic 66 Leukemia, Myeloid, Chronic-Phase 65 Hematologic Neoplasms 65 Dendritic Cell Sarcoma, Interdigitating 62 Lymphoma, B-Cell 59 Blast Crisis 57 Ovarian Neoplasms 56 Triple Negative Breast Neoplasms 53

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡